Clinical trials: NAFLD Cirrhosis
Nonalcoholic Fatty Liver Disease
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.
- Trial name
- NCT02029586
- Testing
- MB12066 200mg
- Where
- 10 sites in South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
Non-alcoholic Steatohepatitis, Hepatic Impairment
A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with…
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Trial name
- NCT05835180
- Testing
- TVB-2640 - 50 mg
- Where
- 3 sites in United States, Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Fatty Liver, Cirrhosis
Development of a Breath Test for Monitoring Patients With Liver Disease
The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.
- Trial name
- NCT00244569
- Testing
- 13C-Methacetin, Breath ID Machine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Virginia Commonwealth University
Moderate Liver Impairment, Severe Liver Impairment
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment.
- Trial name
- NCT04634149
- Testing
- BMS-986036
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis
Treating Nonalcoholic Steatohepatitis (NASH) With Metformin
Nonalcoholic Steatohepatitis (NASH) is associated with progressive liver disease, fibrosis, and cirrhosis. Although the cause of NASH is unknown, it is often associated with obesity, type 2 diabetes, and insulin resistance.
- Trial name
- NCT00063232
- Testing
- Metformin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis B, Hepatic Fibrosis
Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD
Hepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C.
- Conditions
- Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver
- Trial name
- NCT02031913
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Boramae Hospital
Liver Diseases, Alcoholic, Fibrosis
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients…
- Trial name
- SIPHON (NCT03308916)
- Testing
- transient elastography, Enhanced liver fibrosis test, Indirect serum markers of liver fibrosis
- Where
- Denmark
- Volunteers
- 6,500 people
- Sponsor
- Maja Thiele
Non-alcoholic Steatohepatitis, Fatty Liver
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
To evaluate the safety and tolerability of Nitazoxanide (NTZ) 500mg Twice Daily (BID) after 24 weeks of treatment in patients with NASH induced Stage 2 or Stage 3 fibrosis
- Conditions
- Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
- Trial name
- NCT03656068
- Testing
- Nitazoxanide 500mg BID
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Pinnacle Clinical Research, PLLC
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Nonalcoholic Steatohepatitis
Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis
The purpose of this study is to evaluate the effects of solithromycin on hepatic histology and biomarkers in patients with nonalcoholic steatohepatitis.
- Trial name
- NCT02510599
- Testing
- solithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Melinta Therapeutics, Inc.
Nonalcoholic Steatohepatitis
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M…
- Trial name
- FORTUNA (NCT05809934)
- Testing
- AZD2693
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Affecting approximately one-third of the United States (U.S.) population, the prevalence of NAFLD increases to 90% in patients with…
- Conditions
- Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound
- Trial name
- NCT04820036
- Testing
- Insulin Resistance, Quality of Life Assessment, Liver Function Test
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis
In a retrospective study, 200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fatty liver fibrosis have been identified for pathological diagnosis of liver histology and exclusion of other liver…
- Trial name
- NCT03842748
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Non Alcoholic Steatohepatitis, Hyperuricemia
Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia
This study aims at evaluating and comparing the protective outcomes of using Febuxostat versus Vitamin E in Hyperuricemia non-alcoholic steatohepatitis patients without cirrhosis.
- Trial name
- NCT05574036
- Testing
- Febuxostat 80 MG Oral Tablet, vit E
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Tanta University
NAFLD, Liver Fibrosis
Different Doses of ZED1227 vs. Placebo in NAFLD
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will…
- Trial name
- NormaliZED (NCT05305599)
- Testing
- ZED1227
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Dr. Falk Pharma GmbH
NAFLD, Inflammatory Bowel Diseases
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume little or no alcohol.
- Conditions
- NAFLD, Inflammatory Bowel Diseases, Steatosis, Fibrosis, Liver
- Trial name
- PONI (NCT06814600)
- Testing
- Transient elastometry
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
NASH - Nonalcoholic Steatohepatitis, Liver Fibroses
Liquid Biopsy for NASH and Liver Fibrosis
Nonalcoholic fatty liver disease (NAFLD) has evolved to represent the most common cause of chronic liver disease globally. Today, NAFLD is a leading indication for liver transplantation and a major etiology for hepatocellular…
- Trial name
- LIBRA (NCT04677101)
- Testing
- Liver Biopsy
- Where
- 2 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
NAFLD Cirrhosis
Dapagliflozin in Non Alcoholic Fatty Liver Disease Associated Cirrhosis and Its Role in Preventing Development of Chronic Kidney Disease.
The role of Dapagliflozin in the improvement in CKD in both diabetic and non-diabetic patients has been evaluated in the past. SGLT2i have also been found to be beneficial in NAFLD patients in improving the liver function…
- Trial name
- NCT05849220
- Testing
- Dapagliflozin, Standard of Care
- Where
- India
- Volunteers
- 144 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-Alcoholic Fatty Liver Disease, Childhood Obesity
Clinical Epidemiology of NAFLD in Children and Adolescents
Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly increasing alongside overweight and obesity, not only in adults but also in children and adolescents.
- Trial name
- LiverKids (NCT05526274)
- Testing
- Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)
- Where
- Spain
- Volunteers
- 2,866 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina